Human Leukemia Cell HL-60 based Proliferation Assay Service
Creative Biolabs delivers actionable pharmacological data, moving your therapeutic candidates through preclinical evaluation faster with minimal translational risk. The HL-60 model, derived from acute promyelocytic leukemia (APL), provides a crucial and clinically relevant in vitro system. This model is ideal for evaluating agents that target rapidly proliferating hematopoietic malignancies by delivering essential inhibitory concentration 50% (IC50) and growth inhibition concentration 50% (GI50) data. We use this system to validate your lead compounds, ensuring your pipeline proceeds confidently.
The Critical Relevance of the HL-60 Model
The HL-60 cell line, derived from APL, is the gold standard for studying myeloid cell biology. Its key advantage is the capacity for induced differentiation, making it an indispensable tool for analyzing pathways involved in proliferation, differentiation, and apoptosis. The line provides a reliable platform for drug efficacy screening against rapidly dividing hematopoietic malignancies. By utilizing HL-60, our clients gain immediate access to a model that reflects a critical human leukemia subtype, minimizing translational risk for small molecules, biologics, and novel immunotherapies.
Key Deliverables and Problem-Solving Capabilities
Our service provides clear, quantitative metrics essential for go/no-go decisions in lead optimization:
Quantitative Potency Ranking
We provide accurate IC50 values, including GI50, TGI (total growth inhibition, indicating cytostasis), and LC50 (lethal concentration 50%, indicating cytotoxicity). These metrics allow for a data-driven comparison and prioritization of your compounds.
High-Throughput Confidence
Our optimized luminescence based platform is automation-ready and minimizes experimental variability, ensuring every result is scalable from small-scale characterization to full HTS campaigns.
Mechanistic Differentiation Analysis
Leveraging the HL-60 cell line's unique capacity, we help determine if your compound induces differentiation-dependent apoptosis. This is crucial for understanding the therapeutic potential of agents that aim to force cancer cells to mature and die, a highly desirable mechanism of action (MoA) in leukemia.
Engage our expert team today to discuss your screening requirements and accelerate your lead compound from discovery to optimization.
Workflow: From Compound Submission to Final Report
This systematic approach transforms your submitted compounds and requirements into actionable pharmacological reports, providing full transparency from cell preparation through final data modeling.
Publication
The study showed that crocin, a carotenoid from saffron extract, exhibits considerable anti-tumor activity against HL-60 cells both in vitro and in vivo. Studies have demonstrated crocin's ability to inhibit cell proliferation and induce apoptosis via modulating the expression of apoptotic markers like Bcl-2 and Bax. These exciting findings substantiate the potency of HL-60 based assays in uncovering therapeutic potential and mechanistic pathways of anti-cancer compounds.
Fig.1 Crocin suppresses the proliferation of the HL-60 human promyelocytic leukemia cell line. 1
Why Choose Us
Creative Biolabs is the industry leader for HL-60 functional assays, combining specialized experience and proprietary technology. With decades of immuno-oncology focus, we expertly interpret the subtle biological responses of this line, ensuring data relevance. Our primary luminescence HTS platform offers superior sensitivity and dynamic range over older colorimetric assays (MTT/WST), enabling reliable detection even for compounds with marginal potency. Furthermore, we demonstrate versatility in complex modalities, routinely handling synergistic drug combinations and advanced delivery systems, as validated by our published data.
Ready to leverage a platform that minimizes variability and maximizes data confidence? Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q: Can this assay be adapted for complex combination therapies or agents that require physical stimulus for activation?
A: Absolutely. Our platform is flexible, as demonstrated by our success with agents like nanodiamonds requiring blue light activation. We specialize in designing custom protocols to accurately assess the synergistic effects of multiple agents or conditions, ensuring the MoA is fully captured.
Q: Does the service include analysis of differentiation markers to confirm the MoA?
A: While the core proliferation assay identifies the anti-growth effect, we highly recommend integrating our downstream functional validation services. This includes FACS analysis for myeloid differentiation markers.
Q: What is the primary advantage of using a luminescence based assay over traditional methods like MTT?
A: Luminescence assays, which quantify cellular ATP, offer superior sensitivity and a wider dynamic range than colorimetric methods. This is critical for reliable detection in high-throughput settings and ensures that the observed inhibition is a true biological effect.
Customer Review
-
MoA Confirmation
Using Creative Biolabs' service in our research has significantly facilitated the confirmation of our lead compound's differentiation mechanism. The downstream CD14 and CD11b marker analysis, combined with the LC50 determination, was essential for defining our compound's unique therapeutic profile. – Ain*ger -
Complex Systems Evaluation
Using Creative Biolabs' service in our research has significantly improved the evaluation of our targeted nanodiamond delivery system. The HTS format allowed us to efficiently test various drug-to-nanoparticle ratios and the combined effect of physical stimuli, saving us critical development time. – Su*san
Related Services
To fully characterize and advance your anti-leukemic candidates, Creative Biolabs recommends leveraging these complementary services:
Quality Control for In Vivo Assays
Creative Biolabs provides a sophisticated in vivo cell and gene therapy service platform. We conduct programs with rigorous QC from design to data interpretation.
Learn More →Target Discovery and Validation
Creative Biolabs combines genomics with sophisticated cell analysis to quickly identify and validate drug targets in virtually any biological matrix for various cancers.
Learn More →Contact Us
Creative Biolabs' HL-60 based proliferation assay service provides the critical confluence of scientific expertise, technological superiority, and deep mechanistic insight needed to advance your therapeutic pipeline. We deliver the precise, high-confidence data required for informed decision-making in lead optimization.
To discuss your specific project requirements, customized assay design, or complex compound screening needs, please reach out to our team today.
Reference
- Sun, Yan, et al. "Crocin exhibits antitumor effects on human leukemia HL‑60 cells in vitro and in vivo." Evidence‑based Complementary and Alternative Medicine 2013.1 (2013): 690164. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.1155/2013/690164
Download our brochure